A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Clinical trial NCT05132582 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05132582
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-07
- Primary completion
- 2025-09-05
- Enrollment
- 654
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.